Publications scientifiques

Les publications réalisées en collaboration CNRS/MEDESIS :

Systemic delivery of P42 peptide: a new weapon to fight Huntington’s disease.Acta Neuropathol Commun. (2014)

The P42 peptide and Peptide-based therapies for Huntington’s disease. Orphanet Journal of Rare Diseases (2016)

Couly S1, Paucard A1, Bonneaud N1, Maurice T1, Benigno L2, Jourdan C1, Cohen-Solal C3, Vignes M3, Maschat F ; Improvement of BDNF signaling by P42 peptide in Huntington’s disease – Hum Mol Genet. (2018)

Télécharger

Exposure of R6/2 mice in an enriched environment augments P42 therapy efficacy on Huntington’s disease progression. Neuropharmacology ; Volume 186, (15 March 2021)

Télécharger

Nous présentons ci-dessous une liste de publications dans lesquelles des membres de Medesis Pharma sont co-auteurs, ou dans lesquelles la plateforme de délivrance Aonys® est mentionnée.

Wilson EN, Do Carmo S, Welikovitch LA, Hall H, Aguilar LF, Foret MK, Iulita F, Jia DT, Marks AR, Allard S, Emmerson JT, Ducatenzeiler A, and Cuello C

NP03, a microdose Lithium Formulation, Blunts Early Amyloid Post-Plaque Neuropathology in McGill-R-Thy1-APP Alzheimer-Like Transgenic Rats – J. of Alzheimer’s Disease, 73 (2020) 723-739.

Wilson EN, Do Carmo S, Iulita MF, Hall H, Austin G, Jia D, Malcolm J, Foret M, Marks AR, Butterfield D and Cuello C

Microdose Lithium NP03 Diminishes Pre-Plaque Oxidative Damage and Neuroinflammation in a Rat model of Alzheimer’s-like Amyloidosis – Current Alzheimer Research, 2018, 15, 1220-1230.

Aroa Relaño-Ginés, Sylvain Lehmann, Elsa Brillaud, Maxime Belondrade, Danielle Casanova, Claire Hamela, Charles Vincent, Sophie Poupeau, Jerome Sarniguet, Maria-Teresa Alvarez-Martinez, Damien Arnaud, Jean-Claude Maurel, and Carole Crozet

Lithium as a disease-modifying agent for prion disease, Translational Psychiatry (2018)

Couly S1, Paucard A1, Bonneaud N1, Maurice T1, Benigno L2, Jourdan C1, Cohen-Solal C3, Vignes M3, Maschat F

Improvement of BDNF signalling by P42 peptide in Huntington’s disease – Hum Mol Genet. (2018)

Wilson EN, Do Carmo S, Iulita MF, Hall H, Ducatenzeiler D, Marks AR , Allard S, Jia DT, Windheim J and Cuello AC.

BACE1 inhibition by microdose lithium formulation NP03 rescues memory loss and early stage amyloid neuropathology

Translational Psychiatry (2017) 7, e1190. Voir l’article ici

Lavaud C, Kajdan M, Compte E, Maurel JC, Lai Kee Him J, Bron P, Oliviero E, Long J, Larionovaa J and Guari Y

In situ synthesis of Prussian blue nanoparticles within a biocompatible reverse micellar system for in vivo Cs+ uptake

New J. Chem., 2017,41, 2887-2890

Marelli C and Maschat F

The P42 peptide and Peptide-based therapies for Huntington’s disease.

Orphanet Journal of Rare Diseases (2016) 11:24. Voir l’article ici.

Mouri A, Legrand P, El Ghzaoui A, Dorandeu C, Maurel JC, Devoisselle JM.

Formulation, physicochemical characterization and stability study of lithium-loaded microemulsion system.

Int J Pharm. 2016 Apr 11;502(1-2):117-24

Mouri A, Diat O, El Ghzaoui A, Ly I, Dorandeu C, Maurel JC, Devoisselle JM, Legrand P.

Developement of pharmaceutical gel based on Peceol, lecithin, ethanol and water : Physicochemical characterization ans stability study.

J Colloid Interface Sci. 2015 Nov 1;457:152-61.

Mouri A, Diat O, El Ghzaoui A, Bauer C, Maurel JC, Devoisselle JM, Dorandeu C, Legrand P.

Phase behavior of reverse microemulsions based on Peceol(®).

J Colloid Interface Sci. 2014 Feb 15;416:139-46.

Mouri A, Diat O, Lerner DA, Ghzaoui AE, Ajovalasit A, Dorandeu C, Maurel JC, Devoisselle JM, Legrand P.

Water solubilization capacity of pharmaceutical microemulsions based on Peceol®, lecithin and ethanol.

Int J Pharm. 2014 Jul 15;475(1-2):324-334.

Lehmann S, Relano-Gines A, Resina S, Brillaud E, Casanova D, Vincent C, Hamela C, Poupeau S, Laffont M, Gabelle A, Delaby C, Belondrade M, Arnaud JD, Alvarez MT, Maurel JC, Maurel P, Crozet C.

Systemic delivery of siRNA down regulates brain prion protein and ameliorates neuropathology in prion disorder.

PLoS One. 2014 Feb 14;9(2):e88797. Voir l’article ici.

Arribat Y, Talmat-Amar Y, Paucard A, Lesport P, Bonneaud N, Bauer C, Bec N, Parmentier ML, Benigno L, Larroque C, Maurel P, Maschat F.

Systemic delivery of P42 peptide: a new weapon to fight Huntington’s disease.

Acta Neuropathol Commun. 2014 Aug 5;2:86. Voir l’article ici.

Pouladi MA, Brillaud E, Xie Y, Conforti P, Graham RK, Ehrnhoefer DE, Franciosi S, Zhang W, Poucheret P, Compte E, Maurel JC, Zuccato C, Cattaneo E, Néri C, Hayden MR.

NP03, a novel low-dose lithium formulation, is neuroprotective in the YAC128 mouse model of Huntington disease.

Neurobiol Dis. 2012 Dec;48(3):282-9.

Julien Champagne, Laetitia K. Linares, Benjamin Maurel, Alexandre Zampieri, Maeva Moreno, Ivanna Fuentes, Emeric Dubois, Dany Severac, Adrien Decorsière, Frédéric Bienvenu.

TAG-RNAi overcomes off-target effects in cancer models.

Springer Nature , Published 26 september 2019.